This is a randomized, double-blind, placebo-controlled Phase I/II study. About 40 participants will be recruited to receive either APG-2575 or a placebo, with doses from 200mg up to 800mg.
Age
18–65
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
1\. Diagnosis of systemic lupus erythematosus for at least 6 months.
2\. On stable treatment for systemic lupus erythematosus before first dose at least 28 days.
3\. SLEDIA-2000 score: 4-12
4.Other than systemic lupus erythematosus, subject should be in general good health.
You may not be if
1\. Severe systemic lupus erythematosus.
2\. Significant autoimmune disease other than lupus.
3\. Significant, uncontrolled or unstable disease in any organ.
Clareo Health | A Study of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus.
